User menu

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

Bibliographic reference Dooley, Ma ; Houssiau, Frédéric ; Aranow, C ; D'Cruz, Dp ; Askanase, A ; et. al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. In: Lupus, Vol. 22, no.1, p. 63-72 (2013)
Permanent URL http://hdl.handle.net/2078.1/122983
  1. Petri Michelle, Stohl William, Chatham Winn, McCune W. Joseph, Chevrier Marc, Ryel Jeff, Recta Virginia, Zhong John, Freimuth William, Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus, 10.1002/art.23678
  2. Furie Richard, Petri Michelle, Zamani Omid, Cervera Ricard, Wallace Daniel J., Tegzová Dana, Sanchez-Guerrero Jorge, Schwarting Andreas, Merrill Joan T., Chatham W. Winn, Stohl William, Ginzler Ellen M., Hough Douglas R., Zhong Z. John, Freimuth William, van Vollenhoven Ronald F., , A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, 10.1002/art.30613
  3. Navarra Sandra V, Guzmán Renato M, Gallacher Alberto E, Hall Stephen, Levy Roger A, Jimenez Renato E, Li Edmund K-M, Thomas Mathew, Kim Ho-Youn, León Manuel G, Tanasescu Coman, Nasonov Eugeny, Lan Joung-Liang, Pineda Lilia, Zhong Z John, Freimuth William, Petri Michelle A, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(10)61354-2
  4. Tassiulas IO, Kelley’s Textbook of Rheumatology, 1263 (2008)
  5. Ward Michael M., Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995, 10.1001/archinte.160.20.3136
  6. Kasitanon Nuntana, Magder Laurence S., Petri Michelle, Predictors of Survival in Systemic Lupus Erythematosus : , 10.1097/01.md.0000224709.70133.f7
  7. Bernatsky S., Boivin J.-F., Joseph L., Manzi S., Ginzler E., Gladman D. D., Urowitz M., Fortin P. R., Petri M., Barr S., Gordon C., Bae S.-C., Isenberg D., Zoma A., Aranow C., Dooley M.-A., Nived O., Sturfelt G., Steinsson K., Alarcón G., Senécal J.-L., Zummer M., Hanly J., Ensworth S., Pope J., Edworthy S., Rahman A., Sibley J., El-Gabalawy H., McCarthy T., St. Pierre Y., Clarke A., Ramsey-Goldman R., Mortality in systemic lupus erythematosus, 10.1002/art.21955
  8. Hahn Bevra H., McMahon Maureen A., Wilkinson Alan, Wallace W. Dean, Daikh David I., FitzGerald John D., Karpouzas George A., Merrill Joan T., Wallace Daniel J., Yazdany Jinoos, Ramsey-Goldman Rosalind, Singh Karandeep, Khalighi Mazdak, Choi Soo-In, Gogia Maneesh, Kafaja Suzanne, Kamgar Mohammad, Lau Christine, Martin William J., Parikh Sefali, Peng Justin, Rastogi Anjay, Chen Weiling, Grossman Jennifer M., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, 10.1002/acr.21664
  9. Alarcón-Segovia Donato, Tumlin James A., Furie Richard A., McKay James D., Cardiel Mario H., Strand Vibeke, Bagin Robert G., Linnik Matthew D., Hepburn Bonnie, , LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study : LJP 394 for the Prevention of Renal Flare in SLE, 10.1002/art.10763
  10. PETRI M., SINGH S., TESFASYONE H., MALIK A., Prevalence of Flare and Influence of Demographic and Serologic Factors on Flare Risk in Systemic Lupus Erythematosus: A Prospective Study, 10.3899/jrheum.090019
  11. Schur Peter H., Sandson John, Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus, 10.1056/nejm196803072781004
  12. Ter Borg E. J., Horst G., Hummel E. J., Limburg P. C., Kallenberg C. G. M., Measurement of increases in anti-double-stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus, 10.1002/art.1780330505
  13. Tseng Chung-E, Buyon Jill P., Kim Mimi, Belmont H. Michael, Mackay Meggan, Diamond Betty, Marder Galina, Rosenthal Pamela, Haines Kathleen, Ilie Virginia, Abramson Steven B., The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial, 10.1002/art.22198
  14. Dooley Mary Anne, Jayne David, Ginzler Ellen M., Isenberg David, Olsen Nancy J., Wofsy David, Eitner Frank, Appel Gerald B., Contreras Gabriel, Lisk Laura, Solomons Neil, Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, 10.1056/nejmoa1014460
  15. Ginzler Ellen M., Wofsy David, Isenberg David, Gordon Caroline, Lisk Laura, Dooley Mary-Anne, , Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial, 10.1002/art.25052
  16. Sinclair A., Appel G., Dooley M.A., Ginzler E., Isenberg D., Jayne D., Wofsy D., Solomons N., Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS), 10.1177/0961203307084712
  17. Furie Richard A., Petri Michelle A., Wallace Daniel J., Ginzler Ellen M., Merrill Joan T., Stohl William, Chatham W. Winn, Strand Vibeke, Weinstein Arthur, Chevrier Marc R., Zhong Z. John, Freimuth William W., Novel evidence-based systemic lupus erythematosus responder index, 10.1002/art.24698
  18. Stohl William, Hiepe Falk, Latinis Kevin M., Thomas Mathew, Scheinberg Morton A., Clarke Ann, Aranow Cynthia, Wellborne Frank R., Abud-Mendoza Carlos, Hough Douglas R., Pineda Lilia, Migone Thi-Sau, Zhong Z. John, Freimuth William W., Chatham W. Winn, , Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, 10.1002/art.34400